Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/30498230http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/30498230http://www.w3.org/2000/01/rdf-schema#comment"

Background

There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VEGF/VEGFR2 inhibitors (e.g., bevacizumab and sunitinib) for metastatic RCC; and in combination with chemotherapeutics as neoadjuvant (preoperative) therapies for resectable TNBC.

Methods

This study investigated these and similar clinically relevant drug combinations in highly translational preclinical models of micro- and macro-metastatic disease that spontaneously develop after surgical resection of primary kidney or breast tumours derived from orthotopic implantation of murine cancer cell lines (RENCAluc or EMT-6/CDDP, respectively).

Results

In the RENCAluc model, adjuvant sunitinib plus anti-PD-L1 improved overall survival compared to either drug alone, while the same combination was ineffective as early therapy for unresected primary tumours or late-stage therapy for advanced metastatic disease. In the EMT-6/CDDP model, anti-PD-L1 was highly effective as an adjuvant monotherapy, while its combination with paclitaxel chemotherapy (with or without anti-VEGF) was most effective as a neoadjuvant therapy.

Conclusions

Our preclinical data suggest that anti-PD-L1 plus sunitinib may warrant further investigation as an adjuvant therapy for RCC, while anti-PD-L1 may be improved by combining with chemotherapy in the neoadjuvant but not the adjuvant setting of treating breast cancer."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.org/dc/terms/identifier"doi:10.1038/s41416-018-0297-1"xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Xu P."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Man S."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Chow A."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Kerbel R.S."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Kruger J."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Pham E."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Khan K.A."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Paez-Ribes M."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/author"Wu F.T.H."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/date"2019"xsd:gYear
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/name"Br J Cancer"xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/pages"196-206"xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/title"Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease."xsd:string
http://purl.uniprot.org/citations/30498230http://purl.uniprot.org/core/volume"120"xsd:string
http://purl.uniprot.org/citations/30498230http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/30498230
http://purl.uniprot.org/citations/30498230http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/30498230
http://purl.uniprot.org/uniprot/#_Q0GN75-mappedCitation-30498230http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/30498230
http://purl.uniprot.org/uniprot/#_Q9NZQ7-mappedCitation-30498230http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/30498230
http://purl.uniprot.org/uniprot/Q0GN75http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/30498230
http://purl.uniprot.org/uniprot/Q9NZQ7http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/30498230